Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.6M Sell
161,700
-34,300
-18% -$2.67M ﹤0.01% 1579
2026
Q2
$14.6M Buy
196,000
+15,000
+8% +$1.05M ﹤0.01% 1355
2026
Q1
$13.4M Buy
+181,000
New +$13.1M 0.01% 1292
2025
Q1
– Sell
-40,000
Closed -$1.1M – 5587
2024
Q4
$1.1M Buy
+40,000
New +$1.03M ﹤0.01% 3294
2024
Q2
– Sell
-29,900
Closed -$925K – 5578
2024
Q1
$925K Hold
29,900
– – ﹤0.01% 3092
2023
Q4
$1.21M Buy
29,900
+1,500
+5% +$45K ﹤0.01% 2666
2023
Q3
$749K Buy
+28,400
New +$806K ﹤0.01% 2748
2022
Q4
– Sell
-39,100
Closed -$389K – 5774
2022
Q3
$389K Buy
+39,100
New +$406K ﹤0.01% 3415

Other funds holding BBIO

Citigroup's BBIO Position: Q3 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 94% in Q3 2026, buying an estimated $63.3M and bringing the position to 1,676,463 shares worth $110M. The position accounts for 0.04% of the portfolio, ranked #466.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 29 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Citigroup held 1,676,463 shares of BridgeBio Pharma worth $110M as of Q3 2026.
  • Citigroup bought 812,362 BridgeBio Pharma shares in Q3 2026, an estimated $63.3M.
  • BridgeBio Pharma made up 0.04% of Citigroup's portfolio in Q3 2026, its #466 holding.
  • Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 29 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.